Paper40918151
CircASH1L-mediated tumor progression in triple-negative breast cancer: PI3K/AKT pathway mechanisms.
Liu H and 9 others. Open Med (Wars), 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. CircASH1L-mediated tumor progression in triple-negative breast cancer: PI3K/AKT pathway mechanisms. Papers, record 40918151. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40918151
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- CircASH1L-mediated tumor progression in triple-negative breast cancer: PI3K/AKT pathway mechanisms.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 24729100 | Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells. | Apoptosis | 2014 | https://conductscience.org/library/papers/24729100 | PubMed |
| 2 | 31690584 | LncRNA-mediated regulation of SOX9 expression in basal subtype breast cancer cells. | RNA | 2020 | https://conductscience.org/library/papers/31690584 | PubMed |
| 3 | 37415164 | Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. | Mol Cancer | 2023 | https://conductscience.org/library/papers/37415164 | PubMed |
| 4 | 37968332 | Non-coding RNAs in disease: from mechanisms to therapeutics. | Nat Rev Genet | 2024 | https://conductscience.org/library/papers/37968332 | PubMed |
| 5 | 37792593 | Triple-Negative Breast Cancer: Histopathologic Features, Genomics, and Treatment. | Radiographics | 2023 | https://conductscience.org/library/papers/37792593 | PubMed |
| 6 | 39107323 | Piperine enhances doxorubicin sensitivity in triple-negative breast cancer by targeting the PI3K/Akt/mTOR pathway and cancer stem cells. | Sci Rep | 2024 | https://conductscience.org/library/papers/39107323 | PubMed |
| 7 | 38799250 | Role of ICAM-1 in triple-negative breast cancer. | Open Med (Wars) | 2024 | https://conductscience.org/library/papers/38799250 | PubMed |
| 8 | 32264877 | The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer. | Mol Cancer | 2020 | https://conductscience.org/library/papers/32264877 | PubMed |
| 9 | 38065194 | Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study. | Lancet | 2024 | https://conductscience.org/library/papers/38065194 | PubMed |
| 10 | 38029538 | A novel axis of circKIF4A-miR-637-STAT3 promotes brain metastasis in triple-negative breast cancer. | Cancer Lett | 2024 | https://conductscience.org/library/papers/38029538 | PubMed |
| 11 | 37660039 | Advances in immunotherapy for triple-negative breast cancer. | Mol Cancer | 2023 | https://conductscience.org/library/papers/37660039 | PubMed |
| 12 | 38651302 | Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist. | Histopathology | 2024 | https://conductscience.org/library/papers/38651302 | PubMed |
| 13 | 33481008 | circGFRA1 affects the sensitivity of triple-negative breast cancer cells to paclitaxel via the miR-361-5p/TLR4 pathway. | J Biochem | 2021 | https://conductscience.org/library/papers/33481008 | PubMed |
| 14 | 38859856 | circBRAF promotes the progression of triple-negative breast cancer through modulating methylation by recruiting KDM4B to histone H3K9me3 and IGF2BP3 to mRNA. | Am J Cancer Res | 2024 | https://conductscience.org/library/papers/38859856 | PubMed |
| 15 | 32192494 | Noncoding RNAs in gastric cancer: implications for drug resistance. | Mol Cancer | 2020 | https://conductscience.org/library/papers/32192494 | PubMed |
| 16 | 36176752 | Aberrant calcium signalling downstream of mutations in TP53 and the PI3K/AKT pathway genes promotes disease progression and therapy resistance in triple negative breast cancer. | Cancer Drug Resist | 2022 | https://conductscience.org/library/papers/36176752 | PubMed |
| 17 | 32976598 | Coexistence of two quadruplex-duplex hybrids in the PIM1 gene. | Nucleic Acids Res | 2020 | https://conductscience.org/library/papers/32976598 | PubMed |
| 18 | 31054369 | Creatine based polymer for codelivery of bioengineered MicroRNA and chemodrugs against breast cancer lung metastasis. | Biomaterials | 2019 | https://conductscience.org/library/papers/31054369 | PubMed |
| 19 | 32893525 | Roles of miRNA and lncRNA in triple-negative breast cancer. | J Zhejiang Univ Sci B | 2020 | https://conductscience.org/library/papers/32893525 | PubMed |
| 20 | 35580441 | Eriodictyol inhibits breast carcinogenesis by targeting circ_0007503 and repressing PI3K/Akt pathway. | Phytomedicine | 2022 | https://conductscience.org/library/papers/35580441 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40918151
GET https://conductscience.org/api/papers/v1/40918151/references?page=2